Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Regulatory News (PRM)

Share Price Information for Proteome (PRM)

Share Price is delayed by 15 minutes
Get Live Data
1.61    0.01 (0.63%)
Bid:
1.61
Ask:
2.00
Spread: 0.39 (24.224%)
Market Cap: £5.65m
PRM Live PriceLast checked at - London Stock Exchange

Intraday Proteome Share Chart

Directorate Change

23 Dec 2009 15:55

RNS Number : 6704E
Proteome Sciences PLC
23 December 2009
Β 

ο»Ώ

Proteome Sciences plcΒ 

("Proteome Sciences" or "the Company")

Resignation of DirectorΒ 

andΒ 

Appointment of Chief Operating Officer

23rdΒ DecemberΒ 2009: The Board ofΒ Proteome SciencesΒ announces that Dr. Peter Schulz-Knappe will be leavingΒ Proteome SciencesΒ R&D GmbH & Co. KGΒ on 31stΒ DecemberΒ 2009Β in order to be based more closely to his family, at which point he willΒ resign as a director from the Company. The directors would like to thank Dr. Schulz-Knappe for his considerable contribution to the Company's progress and wish him every success in the future.

The CompanyΒ is pleased to announce thatΒ Dr.Β Ian Pike has been appointed Chief Operating Officer ofΒ theΒ CompanyΒ and its subsidiaries andΒ thatΒ Dr. Hans-Dieter Zucht has been appointed as Chief Technical Officer ofΒ Proteome SciencesΒ R&D GmbH Co. KG in Frankfurt. Neither of these are appointments to the board of Proteome Sciences.

Ends

For further information please contact:Β 

Proteome Sciences plc

www.proteomics.com

Tel: +44Β (0)1932 865065

Christopher Pearce, Chief Executive

James Malthouse, Finance DirectorΒ 

Dr. Ian Pike, ChiefΒ OperatingΒ Officer

Email:Β christopher.pearce@proteomics.com

Email: james.malthouse@proteomics.com

Email:Β ian.pike@proteomics.com

Public Relations

IKON AssociatesΒ 

Adrian Shaw

Tel: +44Β (0)1483 271291

Mobile: +44Β (0)797 9900733

Email: adrian@ikonassociates.com

Redleaf Communications Ltd.Β 

Samantha Robbins / Anna DunkinΒ 

Tel: +44Β (0)20 7566 6700

Email: proteome@redleafpr.com

Nominated Adviser

Noble & Company Ltd.

John Llewellyn-Lloyd

Tel: +44Β (0)20 7763 2200

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
BOAEXLFLKLBEFBZ
Date   Source Headline
1st Jun 20267:00 amRNSDirectorate Changes
14th May 202612:55 pmRNSResult of AGM
14th May 202612:00 pmRNSAnnual General Meeting Statement
15th Apr 20267:00 amRNSFinal results for the year ended 31 December 2025
4th Feb 202611:08 amRNSHolding(s) in Company
3rd Feb 202612:43 pmRNSHolding(s) in Company
28th Jan 20263:31 pmRNSResult of Oversubscribed Retail Offer
26th Jan 20267:05 amRNSRetail Offer to raise up to £60,000
26th Jan 20267:00 amRNS£840,000 Fundraise and Retail Offer
6th Jan 20267:00 amRNSTwo Further Substantial Contracts for PRM
8th Dec 20257:00 amRNSSubstantial contract for Proteome Sciences
25th Nov 20257:00 amRNSAppointment of Nominated Adviser and Broker
25th Sep 20257:00 amRNSInterim Results
16th May 20251:17 pmRNSResult of AGM
16th May 202512:00 pmRNSAGM Statement
10th Apr 20257:00 amRNSFinal Results
4th Apr 20251:00 pmRNSNotice of Results and Investor Presentation
21st Feb 20257:00 amRNSContract Win
23rd Dec 20247:08 amRNSLoan Facility, Trading Update & Directorate Change
13th Sep 20247:00 amRNSInterim Results and Directorate Change
16th May 20241:10 pmRNSResult of AGM
16th May 20247:00 amRNSAGM Statement
26th Apr 20247:00 amRNSContract Win
10th Apr 20247:00 amRNSFinal Results
2nd Jan 20247:00 amRNSCompletion of new facility in San Diego
30th Nov 20237:00 amRNSTrading Update
2nd Oct 20237:00 amRNSLaunch of Single Cell Proteomics Services
30th Aug 20232:14 pmRNSInvestor Presentation
25th Aug 20237:00 amRNSInterim Results
1st Jun 20239:43 amRNSRepayment of Loan
17th May 20231:05 pmRNSResult of AGM
17th May 20237:00 amRNSAGM Statement
12th May 20237:00 amRNSExpansion into the US
14th Apr 202310:45 amRNSDirector/PDMR Shareholding
6th Apr 202311:34 amRNSDirector/PDMR Shareholding
6th Apr 202310:30 amRNSInvestor Presentation
4th Apr 20237:00 amRNSFinal Results
29th Mar 20237:00 amRNSNotice of Results
6th Mar 20234:35 pmRNSPrice Monitoring Extension
20th Feb 20237:00 amRNSTrading Update
5th Jan 20237:00 amRNSMilestone Payment for TMT®/TMTpro™ Sales
1st Dec 20224:38 pmRNSGrant of Options and PDMR/director shareholdings
12th Oct 20227:00 amRNSGrant of Options and PDMR/director shareholdings
4th Oct 20227:00 amRNSChange of Auditor
20th Sep 20224:40 pmRNSSecond Price Monitoring Extn
20th Sep 20224:35 pmRNSPrice Monitoring Extension
18th Aug 20227:00 amRNSAppointment of Chief Financial Officer
11th Aug 20227:00 amRNSInvestor Presentation
4th Aug 20227:00 amRNSInterim Results
3rd Aug 20227:00 amRNSMilestone towards Single Cell Proteomics services

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.